848186-99-2

Basic information

• Product Name: 4-Isoxazolecarboxamide, 3-(2,6-dichlorophenyl)-N-[4-(diethylamino)-2-methoxyphenyl]-5-methyl-
• CAS NO: 848186-99-2
• Molecular Formula: C22H23Cl2N3O3
• Molecular Weight: 448.349
• Mol File: 848186-99-2.mol

Chemical Properties

• CAS DataBase Reference: 4-Isoxazolecarboxamide, 3-(2,6-dichlorophenyl)-N-[4-(diethylamino)-2-methoxyphenyl]-5-methyl-(CAS DataBase Reference)
• NIST Chemistry Reference: 4-Isoxazolecarboxamide, 3-(2,6-dichlorophenyl)-N-[4-(diethylamino)-2-methoxyphenyl]-5-methyl-(848186-99-2)
• EPA Substance Registry System: 4-Isoxazolecarboxamide, 3-(2,6-dichlorophenyl)-N-[4-(diethylamino)-2-methoxyphenyl]-5-methyl-(848186-99-2)

Safety Data

• Hazardous Substances Data: 848186-99-2(Hazardous Substances Data)

Upstream product

• 6579-27-7 2,6-dichlorobenzohydroximoyl chloride 
• 24248-21-3 ethyl 3-(2,6-dichlorophenyl)-5-methyl-1,2-oxazole-4-carboxylate 
• 2165-85-7 N¹,N¹-diethyl-3-methoxybenzene-1,4-diamine 
• 3919-76-4 3-(2,6-dichloro-phenyl)-5-methyl-isoxazole-4-carboxylic acid 

Relevant articles and documents

TREAMENT FOR CHEMICAL SUBSTANCE ADDICTION

The present invention provides a method for the treatment of chemical substance abuse by selectively inhibiting ghrelin activity in humans comprising administering to a human in need thereof a therapeutically-effective amount of a ghrelin receptor ligand (GHS-RL). The ghrelin receptor ligand (GHS-RL) can be selected from the group consisting of a ghrelin receptor antagonist (GHS-RA), a ghrelin receptor inverse agonist (GHS-RIA), and a ghrelin receptor partial agonist (GHS-RPA). More specifically, the invention provides a method for treating alcohol related disorders in humans comprising administering to a human in need thereof a therapeutically-effective amount of a compound which is a ghrelin receptor ligand (GHS-RL), such as a ghrelin receptor antagonist (GHS-RA), a ghrelin receptor inverse agonist (GHS-RIA) and a ghrelin receptor partial agonist (GHS-RPA).

Isoxazole carboxamide derivatives as ghrelin receptor modulators

The present invention is related to compounds of formula (I), or a therapeutically suitable salt or prodrug thereof, the preparation of the compounds, compositions containing the compounds and the use of the compounds in the prevention or treatment of disorders regulated by ghrelin including anorexia, cancer cachexia, eating disorders, age-related decline in body composition, weight gain, obesity, and diabetes mellitus.

Synthesis and structure-activity relationships of isoxazole carboxamides as growth hormone secretagogue receptor antagonists

A series of isoxazole carboxamide derivatives has been developed as potent ghrelin receptor antagonists. The synthesis and structure-activity relationship (SAR) are described.